O Γενικός Δείκτης Τιμών έκλεισε στις 854,80 μονάδες με κέρδη 0,78%
Lavipharm: Focus on the development, production and sale of pharmaceutical products
Lavipharm’s financial figures were presented by the Group’s CFO Vasilis Baloumis, during the annual analyst briefing at the Athens Stock Exchange. The figures reflect dynamic